AR and glioblastoma: Importantly, AR protein, not mRNA, expression was dramatically decreased by ALZ003, not enzalutamide, treatment in a dose-dependent manner in TMZ-sensitive and -resistant cells (Fig. 2E and Supplementary Figs. S1C–D), suggesting that, in part, ALZ003 inhibits glioblastoma through decreasing the protein level of AR without affecting gene transcription of AR.